Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Vernova Inc (GEV) vs Revvity Inc (RVTY) Price & Performance

GE Vernova IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

GE Vernova Inc vs Revvity Inc — how do they compare? GE Vernova Inc trades at $1,038.74 (market cap $269.50B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: GE Vernova Inc is far larger — about 20.9× Revvity Inc's market cap, and Revvity Inc pays the higher dividend (0.24%). Which is the better fit depends on your goals.

GEVRVTY
Market Cap
$269.50B$12.91B
Sector
TechnologyTechnology
52-Week High
$1.17K$117.75
52-Week Low
$547.96$82.26
Enterprise Value
$259.17B$15.23B
Dividend Yield
0.2%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Vernova Inc

GE Vernova (GEV) trades at $1,042.98, up 5.26% over 24 hours, reflecting strong momentum near its pivot point of $1,017. The stock exhibits bullish technical signals with moving averages supporting the uptrend. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $17.44 significantly exceeding expectations, though Q2 2026 saw a miss. Revenue growth is solid, projected to rise from $38.07B in 2025 to $41.4B in 2026, while net income margin expanded to 23.04%. The company benefits from a massive $176 billion backlog, positioning it to capitalize on AI-driven power demand.

Outlook remains positive given GEV's strategic role in addressing AI infrastructure bottlenecks, but high valuations (P/E 29.01, EV/EBITDA 86.33) pose risks if execution falters. Analyst consensus is strongly bullish with a $1,270 price target, though investors should monitor quarterly execution against lofty expectations and competitive pressures in the energy sector.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

Read more on GEV

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY